Navigate / EASA
Ask question Discover more Add to collection

GM1 MED.B.095 Medical examination and assessment of applicants for LAPL medical certificates

ED Decision 2019/002/R

DIABETES MELLITUS TYPE 2 TREATED WITH INSULIN – GENERAL

(a)     Pilots and their treating physician should be aware that if the HbA1c target level was set to normal (non-diabetic) levels, this will significantly increase the chance of hypoglycaemia. For safety reasons the target level of HbA1c is therefore set to 7,5–8,5 % even though there is evidence that lower HbA1c levels are correlated with fewer diabetic complications.

(b)     The safety pilot should be briefed pre-flight on the potential condition of the pilot. The results of blood sugar testing before and during flight should be shared with the safety pilot for the acceptability of the values obtained.

Details
Source-Title: GM1 MED.B.095 Medical examination and assessment of applicants for LAPL medical certificates View latest amendments
Erulesid: ERULES-1963177438-11296 Compare versions
Domain: Aircrew
Applicabilitydate: 30 January, 2019
Entryintoforcedate: 29 January, 2019
Regulatorysource: ED Decision 2019/002/R Navigate
Regulatorysubject: Part-MED
Typeofcontent: GM to IR (Guidance material to implementing rule)
Parentir: MED.B.095 Medical examination and assessment of applicants for LAPL medical certificates
Origin: EASA
Category: EAR